Top Qs
Timeline
Chat
Perspective
Cinpanemab
Experimental monoclonal antibody From Wikipedia, the free encyclopedia
Remove ads
Cinpanemab (INN, USAN; developmental code names BIIB054, NI-202) is an anti-α-synuclein drug acting as a monoclonal antibody against α-synuclein which was under development for the treatment of Parkinson's disease.[1][2] It showed no significant influence on disease progression in a 52-week phase 2 clinical trial.[2] The drug reached phase 2 clinical trials but was discontinued in 2021 due its lack of effectiveness.[1][3][2] It was under development by Biogen.[1]
Remove ads
See also
References
External links
Wikiwand - on
Seamless Wikipedia browsing. On steroids.
Remove ads